SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its connection to cannabis culture and biotechnology research, while drawing parallels to Bitcoin. Discussions emphasize the coin's community, long-term vision, and the potential benefits from developments in the cannabis industry. Some users are focused on accumulating the token and touting its potential.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending as it reached new all-time highs, fueled by optimism surrounding robotaxi testing in Austin and expansion plans in Europe. Community discussions revolve around the company's valuation and the potential for further gains, while some express skepticism and highlight competition in the autonomous vehicle space.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is surging amid speculation surrounding potential cannabis rescheduling, driven by reports of President Trump considering an executive order. The community is buzzing with anticipation, with some predicting a significant price increase, while others urge caution, citing previous disappointments. Overall, the stock's movement is tied to the broader cannabis sector's sensitivity to regulatory changes.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amid discussions about its AI capabilities, strategic partnerships (such as with Meta), and potential for growth in the Chinese market. Community members are weighing bullish AI prospects against geopolitical risks and evaluating the stock's valuation. The stock's performance is closely tied to sentiment around Chinese tech and broader economic trends in China.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending amid anticipation for its upcoming earnings report, with community discussions focusing on the potential of its AI initiatives and cloud services to offset declines in its core advertising business. Bullish investors see the company as undervalued, particularly compared to its American counterparts, and highlight its strong cash position and AI capabilities. Bearish sentiment persists, however, with concerns around the Chinese economy and competition in the AI space weighing on overall outlook.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as spot silver prices surge, sparking discussions about potential market squeezes and all-time highs. The community is weighing in on factors like China's silver export policies, increasing industrial demand, and the potential impact of COMEX margin hikes. Some traders are noting technical patterns and anticipating continued upward momentum, while others are wary of a possible pullback.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors discuss its potential amid a challenging Chinese market and debates over its valuation. Community members are weighing opinions on its leadership, potential buybacks, and the broader economic factors impacting its performance relative to peers like Alibaba. Some traders are betting against the stock with puts, while others see it as an undervalued play for long-term growth.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss the potential impact of a pending vote on increasing authorized shares, with some expressing concerns about dilution. However, optimism persists, fueled by the company's Ask Sage acquisition, potential government contracts, and recent institutional buying, leading to speculation about a potential squeeze. The community is actively debating the stock's future trajectory and the significance of upcoming events.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm ($AFRM) is trending as investors discuss its extended partnership with Amazon, highlighting the potential win-win scenario for both companies. Community members are expressing optimism about Affirm's growth prospects and potential to disrupt the credit card industry, while also weighing valuation concerns and the broader competitive landscape in the BNPL sector. Some analysts have reiterated positive ratings and price targets, contributing to the increased attention.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BBIO is trending due to positive analyst upgrades and strong market performance, with discussions focusing on the potential of Attruby and upcoming pipeline catalysts. Community chatter includes speculation about a potential buyout, with some expressing concerns about insider selling while others remain bullish due to upcoming Phase 3 trial results and revenue potential. The stock's technical setup and analyst ratings continue to fuel investor interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance.</li><li>The company now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.</li><li>The company expects its application might be provided a priority review.</li></ul>DBV Technologies (DBVT) said on Tuesday that its late-stage trial evaluating Viaskin Peanut patch for the treatment of peanut allergy in children resulted in significant drop in sensitivity, causing the stock to soar 63% after hours.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://dbv-technologies.com/press_releases/dbv-technologies-announces-positive-topline-results-from-phase-3-vitesse-trial-of-viaskin-peanut-patch-in-peanut-allergic-children-aged-4-7-years/">said</a> that the patch demonstrated a statistically significant treatment effect in children aged 4 to 7 years with 46.6% of children in the VIASKIN Peanut arm meeting the treatment responder criteria after 12 months as compared to just 14.8% children who received placebo. The trial enrolled 654 children, more than the target enrollment of 600, who were then randomised to receive the patch or a placebo.According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful and represent substantial progress towards a well-tolerated, non-invasive potential option.”<h2 class="st-heading-2">Safety Results</h2>Safety results were also consistent with the profile observed in previous trials, the company said.Discontinuations due to adverse effects was 3.2% in patients who received the Viaskin Peanut patch as compared to 0.5% in the placebo arm, it added. While two children expected treatment-related serious adverse events and treatment-related anaphylaxis, they continued treatment, the company said. &nbsp;<h2 class="st-heading-2">Looking Forward</h2>The France-headquartered company, which seeks to develop treatment options for food allergies, now plans to submit an application to the U.S. Food and Drug Administration seeking approval for Viaskin Peanut in the first half of 2026.The company expects its application might be provided a priority review, provided that Viaskin Peanut patch was granted Breakthrough Therapy Designation by the FDA.VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance. The company is also studying the patch in peanut allergic toddlers of 1 through 3 years of age and expects to seek approval for the patch in the age group in the second half of 2026 upon completion of trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DBVT stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.A Stocktwits user highlighted a huge market opportunity, citing the large number of people who are allergic to nuts.<stembedurl>https://www.stocktwits.com/Mushichka/message/639370968</stembedurl>Another sees the stock flying to the moon. “Must be mad crackers if you are even considering shorting this,” they added.<stembedurl>https://www.stocktwits.com/ghcb1981/message/639370886</stembedurl><a href="https://stocktwits.com/symbol/DBVT">DBVT stock</a> has multiplied by about 6 times this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-hits-all-time-high-on-robotaxi-optimism-europe-battery-plans-add-tailwind/cLeJnpgREpg">Tesla Hits All-Time High On Robotaxi Optimism As Wall Street Sees Path To $3T Valuation — Europe Battery Plans Add Tailwind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the DBV Technologies logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing

According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.”

Equity

According to David Fleischer, global principal investigator of the study, the levels of desensitization achieved in the study after one year of treatment are “highly clinically meaningful.”


DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Time to Sell?

DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Here's What Happened...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - What's Next?

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Should You Buy...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Should You Buy?

DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year High - Still a Buy?

DBV Technologies (NASDAQ:DBVT) Sets New 1-Year High - Here's Why...

Vivo Capital LLC Takes Position in DBV Technologies S.A. $DBVT

Vivo Capital LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and...

DBV Technologies (NASDAQ:DBVT) Stock Price Up 7.9% - Should You Buy?

DBV Technologies (NASDAQ:DBVT) Trading Up 7.9% - Here's What Happened...

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Time to Buy?

DBV Technologies (NASDAQ:DBVT) Shares Gap Up - Here's Why...

DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen

Wall Street Zen raised DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday...

DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of "Hold" by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have been assigned a consensus rating of "Hold" from the seven ratings firms that are presently covering the company, Marketbeat...

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

DBV Technologies

Following a massive after-hours gap up of over 70%, traders are closely monitoring the stock for sustained momentum and potential squeeze opportunities.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.32	-$0.24	24.41%	BEAT
Q2 '25	-$0.18	-$0.31	-72.22%	MISSED
Q1 '25	-$0.24	-$0.26	-8.33%	MISSED
Q4 '24	-$0.22	-$0.22	--	EXPECTED

DBVT
DBV Technologies

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest DBVT News

DBVTDBV Technologies